Premium
Aryl hydrocarbon hydroxylase in persons with lung or laryngeal cancer
Author(s) -
Ward Elizabeth,
Paigen Beverly,
Steenland Kyle,
Vincent Ronald,
Minowada Jun,
Gurtoo Hira L.,
Sartori Pam,
Havens Mary Bohne
Publication year - 1978
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910220404
Subject(s) - lung cancer , basal (medicine) , medicine , larynx , gastroenterology , lung , cancer , concomitant , respiratory disease , disease , oncology , surgery , insulin
To test whether the distribution of AHH inducibility is shifted toward the high end of the range in patients who had lung and laryngeal cancer, we measured this trait in 59 patients (32 lung and 27 laryngeal) who had resectable tumors and had been disease‐free for a period of time. The advantage of selecting patients who were free of clinical disease was that measurement of their AHH inducibility should not have been affected by the disease state. Patient and control populations showed no difference in basal and induced AHH activity or AHH inducibility. The mean AHH inducibility in patients who had lung cancer was 3.20±0.20; in patients who had laryngeal cancer 2.96±0.18, and for all controls 3.29±0.04 (no significant difference at p = 0 05). Further analysis of the distribution of AHH inducibility in the patient group compared to controls showed no suggestion of a shift toward the higher end of the range in patients who had lung and laryngeal cancer.